Comments
City-based healthcare major Zydus Cadila on Wednesday informed that the company has received final approval from the US drug regulator, USFDA, to market Pyridostigmine Bromide Tablets USP, 60 mg.
Pyridostigmine Bromide tablets are used in the treatment of various neurological disorders.
According to a company statement, the estimated sales for Pyridostigmine Bromide Tablets USP in 2015 is $27.9 million.
The group now has 100 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare shares were trading at Rs 1,774, up over 2 per cent from the previous close on the BSE.
Ends..
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.